We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Immunobiomarkers in Chronic Rhinosinusitis Correlate with Clinical Severity

By LabMedica International staff writers
Posted on 06 Jul 2022
Print article
Image: The UNI-CAP immunoanalyzer is intended for allergy testing using ImmunoCAP (Photo courtesy of Thermo Fisher Scientific)
Image: The UNI-CAP immunoanalyzer is intended for allergy testing using ImmunoCAP (Photo courtesy of Thermo Fisher Scientific)

Chronic rhinosinusitis comprises a heterogeneous group of inflammatory disorders. It is assumed that the disease process lasts over 12 weeks and is accompanied by two or more symptoms, such as nasal discharge/postnasal drip, nasal congestion, sinus pain/pressure, and anosmia/hyposmia.

Chronic rhinosinusitis (CRS) is characterized by epithelial inflammation and tissue eosinophilic infiltration. Interleukin-5 (IL-5), periostin (POSTN), and IL-33 are important factors that act as chemoattractants for eosinophils, and a tissue-remodeling protein positively correlated with eosinophils in blood and mediators of eosinophilic infiltration.

Clinical Scientists at the Medical University of Lodz (Lodz, Poland) carried out carried out a study in a cohort of 93 Caucasian patients, aged between 22 and 65 years: group I eosinophilic CRS without nasal polyps (CRSsNP) included 53 patients, 13 of whom were diagnosed with allergy; group II eosinophilic CRS with nasal polyps (CRSwNP) included 40 patients, 16 of whom were diagnosed with allergy. In each case, allergy was confirmed by skin prick testing. The reference group was composed of 40 patients with nasal septum deviation (NSD).

Tissue samples were collected during the planned endoscopic procedures. These comprised sinonasal mucosal and polyp tissue from CRS patients, or a fragment of the mucosa of the lower nasal concha from NSD patients. Blood samples were used to evaluate serum IL-5, periostin and IL-33 levels using ELISAs (Thermo Fisher Scientific, Waltham, MA, USA). Tissue samples, after processing, were examined with an Olympus light microscope (Olympus, Tokyo, Japan). The epithelial infiltration with eosinophils were evaluated. Determinations of total IgE levels were performed by an immunoenzymatic method on a UNI-CAP immunoanalyzer (Phadia, Uppsala, Sweden). The expression of IL-5, POSTN and IL-33 mRNA was determined in sinonasal mucosal samples and in nasal polyp tissue by real-time PCR.

The investigators reported that comparison between non-allergic and allergic patients with and without NP show significant differences for total IgE serum levels. NP tissue demonstrated significantly higher IL-5 and POSTN mRNA expression than the sinonasal tissue in the CRSsNP and CRSwNP groups. CRS groups demonstrated elevated IL-33 mRNA expression in comparison to controls irrespective of the presence of NP. No correlation was found between IL-5, POSTN and IL-33 mRNA expression and disease severity. CRSwNP group demonstrated significantly higher serum IL-5, POSTN and IL-33 protein levels than controls, and this corresponds to disease severity.

The authors concluded that serum IL-5, POSTN and IL-33 levels may be useful for identifying CRSwNP patients and predicting the disease severity. Clinical phenotyping of patients with CRS based on selected inflammatory markers could enhance the early recognition of sinus disease, thus representing a promising new therapeutic approach. The study was published on June 25, 2022 in the journal BMC Immunology.

Related Links:
Medical University of Lodz 
Thermo Fisher Scientific

Gold Supplier
Auto Urinary Sediment Analyzer
Automated Nucleic Acid Extraction System
GenoXtract fleXT
Glucose & Lactate Measuremen Device
Microbiology IVD System
MALDI Biotyper Sirius One

Print article


Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.